Literature DB >> 12482519

Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.

Sirid Aimée Kellermann1, Larry L Green.   

Abstract

Technical advances made in the 1980s and early 1990s resulted in monoclonal antibodies that are now approved for human therapy. Novel transgenic mouse strains provide a powerful technology platform for creating fully human monoclonal antibodies as therapeutics; ten such antibodies have entered clinical trials since 1998 and more are in preclinical testing. Improved transgenic mouse strains provide a powerful technology platform for creating human therapeutics in the future.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12482519     DOI： 10.1016/s0958-1669(02)00354-3

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN： 0958-1669            Impact factor:   9.740


  18 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

Review 3.  Topical antimicrobials for burn infections - an update.

Authors:  Mert Sevgi; Ani Toklu; Daniela Vecchio; Michael R Hamblin
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-12

Review 4.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

Review 5.  Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.

Authors:  Trent P Munro; Stephen M Mahler; Edwin P Huang; David Y Chin; Peter P Gray
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

6.  Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Authors:  Hanqiu Zheng; Yangjin Bae; Sabine Kasimir-Bauer; Rebecca Tang; Jin Chen; Guangwen Ren; Min Yuan; Mark Esposito; Wenyang Li; Yong Wei; Minhong Shen; Lanjing Zhang; Nikolai Tupitsyn; Klaus Pantel; Chadwick King; Jan Sun; Jodi Moriguchi; Helen Toni Jun; Angela Coxon; Brendan Lee; Yibin Kang
Journal:  Cancer Cell       Date:  2017-12-11       Impact factor: 31.743

7.  Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

Authors:  Dana D Hu-Lowe; Enhong Chen; Lianglin Zhang; Katherine D Watson; Patrizia Mancuso; Patrick Lappin; Grant Wickman; Jeffrey H Chen; Jianying Wang; Xin Jiang; Karin Amundson; Ronald Simon; Andreas Erbersdobler; Simon Bergqvist; Zheng Feng; Terri A Swanson; Brett H Simmons; John Lippincott; Gerald F Casperson; Wendy J Levin; Corrado Gallo Stampino; David R Shalinsky; Katherine W Ferrara; Walter Fiedler; Francesco Bertolini
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

8.  Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.

Authors:  Laurens A van Meeteren; Midory Thorikay; Simon Bergqvist; Evangelia Pardali; Corrado Gallo Stampino; Dana Hu-Lowe; Marie-José Goumans; Peter ten Dijke
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

9.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

10.  A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer.

Authors:  Niccolò Ravenni; Marcel Weber; Dario Neri
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.